Sparsentan: First Approval

Sparsentan: First Approval

Sparsentan (FILSPARI™) is an oral, dual endothelin angiotensin receptor antagonist that is being developed by Travere Therapeutics for the treatment of immunoglobulin A (IgA) nephropathy and focal segmental glomerulosclerosis (FSGS). In February 2023, sparsentan received accelerated approval in the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drugs (New York, N.Y.) N.Y.), 2023-04, Vol.83 (6), p.563-568
1. Verfasser: Syed, Yahiya Y.
Format: Artikel
Sprache:eng
Schlagworte:
AdisInsight Report
Adult
Angiotensin
Blood pressure
Drug dosages
Drug interactions
Endothelins
Glomerulonephritis, IGA
Glomerulosclerosis, Focal Segmental
Glycoproteins
Health risks
Humans
IgA nephropathy
Immunoglobulin A
Immunoglobulins
Internal Medicine
Medicine
Medicine & Public Health
Pharmaceuticals
Pharmacokinetics
Pharmacology/Toxicology
Pharmacotherapy
Plasma
Proteins
Proteinuria
Spiro Compounds
Sulfonamides
Urine
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Sparsentan (FILSPARI™) is an oral, dual endothelin angiotensin receptor antagonist that is being developed by Travere Therapeutics for the treatment of immunoglobulin A (IgA) nephropathy and focal segmental glomerulosclerosis (FSGS). In February 2023, sparsentan received accelerated approval in the USA for reducing proteinuria in adults with primary IgA nephropathy who are at risk of rapid disease progression. This article summarizes the milestones in the development of sparsentan leading to this first approval for IgA nephropathy.
ISSN:0012-6667
1179-1950
DOI:10.1007/s40265-023-01864-x